Protein tyrosine phosphatase, receptor type B is a potential biomarker and facilitates cervical cancer metastasis via epithelial-mesenchymal transition

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
   PubMed Web of Science ®Google Scholar
• Buskwofie A, David-West G, Clare CA. A review of cervical cancer: incidence and disparities. J Natl Med Assoc. 2020;112:229–232.
   PubMed Web of Science ®Google Scholar
• Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003;16:1–17.
   PubMed Web of Science ®Google Scholar
• Kalliala I, Athanasiou A, Veroniki AA, et al. Incidence and mortality from cervical cancer and other malignancies after treatment of cervical intraepithelial neoplasia: a systematic review and meta-analysis of the literature. Ann Oncol. 2020;31:213–227.
   PubMed Web of Science ®Google Scholar
• Zhou J, Guo X, Chen W, et al. Targeting survivin sensitizes cervical cancer cells to radiation treatment. Bioengineered. 2020;11:130–140.
   PubMed Web of Science ®Google Scholar
• Carota IA, Kenig-Kozlovsky Y, Onay T, et al. Targeting VE-PTP phosphatase protects the kidney from diabetic injury. J Exp Med. 2019;216:936–949.
   PubMed Web of Science ®Google Scholar
• Thomson BR, Carota IA, Souma T, et al. Targeting the vascular-specific phosphatase PTPRB protects against retinal ganglion cell loss in a pre-clinical model of glaucoma. eLife. 2019;8. DOI:10.7554/eLife.48474
   Web of Science ®Google Scholar
• Kim JS, Kim WK, Oh KJ, et al. Protein tyrosine phosphatase, receptor type B (PTPRB) inhibits brown adipocyte differentiation through regulation of VEGFR2 phosphorylation. J Microbiol Biotechnol. 2019;29:645–650.
   PubMed Web of Science ®Google Scholar
• Soady KJ, Tornillo G, Kendrick H, et al. The receptor protein tyrosine phosphatase PTPRB negatively regulates FGF2-dependent branching morphogenesis. Development. 2017;144:3777–3788.
   PubMed Web of Science ®Google Scholar
• Alesi V, Loddo S, Grispo M, et al. Reassessment of the 12q15 deletion syndrome critical region. Eur J Med Genet. 2017;60:220–223.
   PubMed Web of Science ®Google Scholar
• Sahni S, Krisp C, Molloy MP, et al. PSMD11, PTPRM and PTPRB as novel biomarkers of pancreatic cancer progression. Biochim Biophys Acta Gen Subj. 2020;1864:129682.
   PubMed Web of Science ®Google Scholar
• Beca F, Lee SSK, Pareja F, et al. Whole-exome sequencing and RNA sequencing analyses of acinic cell carcinomas of the breast. Histopathology. 2019;75:931–937.
   PubMed Web of Science ®Google Scholar
• Qi Y, Dai Y, Gui S. Protein tyrosine phosphatase PTPRB regulates Src phosphorylation and tumour progression in NSCLC. Clin Exp Pharmacol Physiol. 2016;43:1004–1012.
   PubMed Web of Science ®Google Scholar
• Weng X, Chen W, Hu W, et al. PTPRB promotes metastasis of colorectal carcinoma via inducing epithelial-mesenchymal transition. Cell Death Dis. 2019;10:352.
   PubMed Web of Science ®Google Scholar
• Luo Y, Liu W, Tang P, et al. miR-624-5p promoted tumorigenesis and metastasis by suppressing hippo signaling through targeting PTPRB in osteosarcoma cells. J Exp Clin Cancer Res. 2019;38:488.
   PubMed Web of Science ®Google Scholar
• Li M, Su X, Wang Y, et al. Lineage-negative lymphoma with a helper innate lymphoid cell phenotype. Virchows Arch. 2020;476:285–293.
   PubMed Web of Science ®Google Scholar
• Den Boon JA, Pyeon D, Wang SS, et al. Molecular transitions from papillomavirus infection to cervical precancer and cancer: role of stromal estrogen receptor signaling. Proceedings of the National Academy of Sciences of the United States of America 2015; 112:E3255–64.
   Google Scholar
• Mahata S, Bharti AC, Shukla S, et al. Berberine modulates AP-1 activity to suppress HPV transcription and downstream signaling to induce growth arrest and apoptosis in cervical cancer cells. Mol Cancer. 2011;10:39.
   PubMed Web of Science ®Google Scholar
• Ahn SY, Li C, Zhang X, et al. Mitofusin-2 expression is implicated in cervical cancer pathogenesis. Anticancer Res. 2018;38:3419–3426.
   PubMed Web of Science ®Google Scholar
• Small W Jr., Bacon MA, Bajaj A, et al. Cervical cancer: a global health crisis. Cancer. 2017;123:2404–2412.
   PubMed Web of Science ®Google Scholar
• Qi X, Fu Y, Sheng J, et al. A novel ferroptosis-related gene signature for predicting outcomes in cervical cancer. Bioengineered. 2021;12:1813–1825.
   PubMed Web of Science ®Google Scholar
• Park PJ. ChIP-seq: advantages and challenges of a maturing technology. Nat Rev Genet. 2009;10:669–680.
   PubMed Web of Science ®Google Scholar
• Tomczak K, Czerwińska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19:A68–77.
   PubMedGoogle Scholar
• Huang J, Qian Z, Gong Y, et al. Comprehensive genomic variation profiling of cervical intraepithelial neoplasia and cervical cancer identifies potential targets for cervical cancer early warning. J Med Genet. 2019;56:186–194.
   PubMed Web of Science ®Google Scholar
• Yang K, Xia B, Wang W, et al. A comprehensive analysis of metabolomics and transcriptomics in cervical cancer. Sci Rep. 2017;7:43353.
   PubMed Web of Science ®Google Scholar
• Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29:212–226.
   PubMed Web of Science ®Google Scholar
• Saitoh M. Involvement of partial EMT in cancer progression. J Biochem. 2018;164:257–264.
   PubMed Web of Science ®Google Scholar
• Aiello NM, Kang Y. Context-dependent EMT programs in cancer metastasis. J Exp Med. 2019;216:1016–1026.
   PubMed Web of Science ®Google Scholar
• Singh M, Yelle N, Venugopal C, et al. EMT: mechanisms and therapeutic implications. Pharmacol Ther. 2018;182:80–94.
   PubMed Web of Science ®Google Scholar
• Du B, Shim JS. Targeting Epithelial-Mesenchymal Transition (EMT) to overcome drug resistance in cancer. Molecules. 2016;21. DOI:10.3390/molecules21070965
   Web of Science ®Google Scholar